Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancr...
Oxford Nanopore Technologies announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete ...
Dr. Crystal Proud, Pediatric Neurologist at Children’s Hospital of the King’s Daughters, remarked, “Our evolving understanding of...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to d...
BeiGene, Ltd. announced a new matching adjusted indirect comparison (MAIC) of the efficacy of BRUKINSA® (zanubrutinib) versus acalabrutinib in relapsed...
The residual HCPs are generated by organisms used for making recombinant biopharmaceutical products. They are considered as process-related impurities. Sin...
Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined ...
QIAGEN announced the launch of QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biote...
Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selato...
Global license and collaboration agreement set to advance the development of OSE-230, a monoclonal antibody aimed at resolving chronic inflammation. ...
- Biktarvy Now First and Only INSTI-Based Single-Tablet Regimen That is FDA Approved and DHHS Guideline Recommended for People Who are Virologically ...
Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, an...
In a significant breakthrough for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim's latest Phase II clinical...
© 2025 Biopharma Boardroom. All Rights Reserved.
